Valter Niemelä

Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease?

Valter Niemelä, Anne‐Marie Landtblom, Kaj Blennow et al. · PLoS ONE · 2017 · 60 citations · Full text

Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington’s disease subjects

Stephanie Herman, Valter Niemelä, Payam Emami Khoonsari et al. · Scientific Reports · 2019 · 43 citations · Full text

Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease

Valter Niemelä, Joachim Burman, Kaj Blennow et al. · PLoS ONE · 2018 · 36 citations · Full text

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease

Valter Niemelä, Anne‐Marie Landtblom, Dag Nyholm et al. · Movement Disorders · 2020 · 30 citations · Full text

Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases

Madelene Braun, Gustaf Boström, Martin Ingelsson et al. · Fluids and Barriers of the CNS · 2023 · 28 citations · Full text